Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient
| Autor: | Spencer A, Rm, Szydlo, Pa, Brookes, Kaminski E, Rule S, van Rhee F, Kn, Ward, Geoff Hale, Waldmann H, Jm, Hows, Jr, Batchelor, Jm, Goldman |
|---|---|
| Předmět: |
Adult
Male Adolescent Graft vs Host Disease HLA-C Antigens Disease-Free Survival Lymphocyte Depletion Leukemia Myelogenous Chronic BCR-ABL Positive Humans Transplantation Homologous Lymphocyte Count Bone Marrow Transplantation Proportional Hazards Models Retrospective Studies Immunosuppression Therapy HLA-A Antigens Histocompatibility Testing Graft Survival Histocompatibility Antigens Class I Age Factors Middle Aged Prognosis Survival Analysis Tissue Donors Treatment Outcome HLA-B Antigens Histocompatibility Leukemia Myeloid Chronic-Phase Female Isoelectric Focusing Polymorphism Restriction Fragment Length T-Lymphocytes Cytotoxic |
| Zdroj: | Europe PubMed Central |
| Popis: | Between August 1985 and July 1994, we performed 115 volunteer unrelated donor (VUD) bone marrow transplants (BMT) for first chronic phase (n = 86) or advanced phase (n = 29) chronic myeloid leukemia (CML). Standard serologic HLA typing of potential donors and recipients was supplemented with one-dimensional isoelectric focusing (IEF) for class I proteins, allogenotyping for DR and DQ alleles using DNA restriction fragment length polymorphism (RFLP) analysis, and the measurement of antirecipient major histocompatibility complex (MHC) cytotoxic T-lymphocyte precursor cells in the donors' blood (CTLp assay). Recipients were conditioned for transplantation with a combination of high-dose chemotherapy and total body irradiation (n = 103) or high-dose chemotherapy alone (n = 12). Twenty eight recipients received ex vivo T-cell-depleted marrow, and 84 underwent some form of in vivo T-cell depletion. The probability of severe (grades III or IV) acute graft-versus-host disease (aGVHD) was 24%, and that of extensive chronic graft-versus-host disease (cGVHD), 38%. Proportional hazards regression analysis showed an association between low frequency CTLp and a reduced incidence of severe aGVHD (relative risk [RR], 0.28; P = .0035). The probability of relapse at 3 years was 23%, with first chronic phase disease being independently associated with a lower risk of relapse (RR, 0.71; P = .01). The overall leukemia-free survival (LFS) at 3 years was 37%; the LFS for the first chronic phase and advanced phase recipients was 41% and 26%, respectively. First chronic phase disease (RR, 0.56; P = .063) and the combination of recipient cytomegalovirus (CMV) seronegativity and an IEF-matched donor (RR, 0.48; P = .011) were both associated with improved LFS. The probabilities of survival and LFS for patients under 40 years of age transplanted in first chronic phase from an IEF-matched donor were 73% and 50%, respectively. We conclude that VUD BMT is a reasonable option for patients with CML; when using ex vivo or in vivo T-cell depletion, optimal results are achieved in patients transplanted in chronic phase with marrow from donors without demonstrable class I HLA mismatch and a low CTLp frequency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|